drugset

Drugs / QUETMOLIMAB

Follow last change Apr 2024 re-read 3 minutes ago

QUETMOLIMAB

also known as E6011

Monoclonal antibody targets CX3CL1

Developed for: Crohn disease · rheumatoid arthritis · primary biliary cholangitis
Investigated by: Eisai Inc. · EA Pharma Co., Ltd.

Trials 9

today NCT03733314 · Ph 2 NCT03092765 · Ph 2 NCT02960490 · Ph 2 NCT02960438 · Ph 2 NCT02249078 · Ph 1 NCT02196558 · Ph 1/2 NCT02039063 · Ph 1/2 NCT02146261 · Ph 1 NCT01731275 · Ph 1

201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT02249078	Dec 2014 → Mar 2016	Crohn disease	Eisai Inc.	Withdrawn	No outcome recorded
Phase 1	NCT02146261	Sep → Dec 2013	—	Eisai Inc.	Completed	No outcome recorded
Phase 1	NCT01731275	Aug 2012 → Aug 2013	—	Eisai Inc.	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT02196558	May 2014 → Aug 2016	rheumatoid arthritis	Eisai Inc.	Completed	No outcome recorded
Phase 1/2	NCT02039063	Apr 2014 → Jan 2017	Crohn disease	EA Pharma Co., Ltd.	Completed	No outcome recorded
Phase 24 trials · 3 missed
Phase 2	NCT03733314	Apr 2019 → Mar 2022	Crohn disease	EA Pharma Co., Ltd.	Completed	Missed primary
Phase 2	NCT03092765	May 2017 → Aug 2018	primary biliary cholangitis	EA Pharma Co., Ltd.	Terminated	No outcome recorded
Phase 2	NCT02960490	Nov 2016 → May 2018	rheumatoid arthritis	Eisai Inc.	Completed	Missed primary
Phase 2	NCT02960438	Oct 2016 → Feb 2018	rheumatoid arthritis	Eisai Inc.	Completed	Missed primary

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2016-06-13	Eisai Inc.	Results EISAI PRESENTS LATEST PHASE Ⅰ/Ⅱ DATA ON IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011 RESULTS SUGGEST SAFETY, TOLERABILITY AS WELL AS CLINICAL ACTIVITY IN RHEUMATOID ARTHRITIS AND CROHN'S DISEASE eisai.com ↗

All press releases naming this drug 3 releases

Date	Issuer	Release
2020-10-06	Eisai Inc.	INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCE Adopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)" eisai.com ↗
2018-11-08	Eisai Inc.	Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn’s Disease Concluded, Research Activities Commence eisai.com ↗
2016-06-13	Eisai Inc.	EISAI PRESENTS LATEST PHASE Ⅰ/Ⅱ DATA ON IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011 RESULTS SUGGEST SAFETY, TOLERABILITY AS WELL AS CLINICAL ACTIVITY IN RHEUMATOID ARTHRITIS AND CROHN'S DISEASE eisai.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

Field	Value	Cited text
Known as	QUETMOLIMAB	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297942 ↗
Known as	E6011	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02249078 ↗ 8 NCT02960438 ↗ NCT02039063 ↗ NCT03733314 ↗ NCT02146261 ↗ NCT03092765 ↗ NCT01731275 ↗ NCT02196558 ↗ NCT02960490 ↗
Action	Inhibit	“a novel cell trafficking inhibitor targeting the FKN-CX3 CR1 interaction” PMID 33038062 ↗ Feb 2021
Modality	Monoclonal antibody	“E6011 is a humanized monoclonal antibody targeting fractalkine (FKN), a CX3C chemokine, which regulates leukocyte trafficking during inflammation.” PMID 33599356 ↗ Mar 2021
Route	Intravenous	“30-minute intravenous infusion” NCT01731275 ↗
Target	CX3CL1	“OBJECTIVE: Fractalkine (CX3CL1/FKN) is a chemokine that regulates chemotaxis and adhesion of CX3C chemokine receptor 1 (CX3CR1)-expressing inflammatory cells. We conducted the...” PMID 28681650 ↗ Jul 2017